DITROPAN® (oxybutynin chloride) is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria).

Adults

The usual dose is one 5-mg tablet two to three times a day. The maximum recommended dose is one 5-mg tablet four times a day. A lower starting dose of 2.5 mg two or three times a day is recommended for the frail elderly.

Pediatric patients over 5 years of age

The usual dose is one 5-mg tablet two times a day. The maximum recommended dose is one 5-mg tablet three times a day.

DITROPAN® (oxybutynin chloride) Tablets are supplied in bottles of 100 tablets (NDC 17314-9200-1). Blue scored tablets (5 mg) are engraved with DITROPAN on one side with 92 and 00, separated by a horizontal score, on the other side.

Pharmacist: Dispense in tight, light-resistant container as defined in the USP.

Store at controlled room temperature 59-86°F (15-30°C).

Manufactured by: sanofi-aventis U.S. LLC, Kansas City, MO 64137. Marketed by Ortho Women's Health & Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869. Revised March 2012

Last reviewed on RxList: 4/2/2012
This monograph has been modified to include the generic and brand name in many instances.